Erasca to Present at the Jefferies Global Healthcare Conference
Rhea-AI Summary
Erasca (Nasdaq: ERAS), a clinical-stage precision oncology company targeting RAS/MAPK pathway-driven cancers, will participate in the Jefferies Global Healthcare Conference at the Marriott Marquis in New York.
Management will join a fireside chat on June 3, 2026 at 3:10 p.m. ET, with a live and archived webcast on Erasca.com/events.
Positive
- None.
Negative
- None.
News Market Reaction – ERAS
In the May 27 session, ERAS gained 8.43%, reflecting a notable positive market reaction. Argus tracked a peak move of +6.8% during that session. Our momentum scanner triggered 27 alerts that day, indicating elevated trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 11 | Earnings and pipeline | Negative | -0.6% | Q1 2026 results with widened net loss and RAS franchise investment. |
| May 11 | Clinical collaboration | Positive | +3.2% | Merck collaboration to evaluate ERAS-0015 with KEYTRUDA in solid tumors. |
| May 06 | Investor conference | Neutral | +9.1% | Bank of America health care conference fireside chat and investor meetings. |
| Apr 27 | Phase 1 data | Positive | -48.3% | Positive preliminary Phase 1 dose-escalation data for ERAS-0015 in KRAS tumors. |
| Apr 27 | Data webcast | Neutral | -10.9% | Conference call and webcast to discuss preliminary ERAS-0015 Phase 1 data. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news shows mixed reactions: positive clinical data and collaborations sometimes saw sharp selloffs, while conference-related visibility previously coincided with a strong gain.
Over the last months, Erasca reported Q1 2026 results on May 11, highlighting a widened net loss driven by a $150.0 million in‑process R&D charge but liquidity of $408.5 million funding operations into H2 2028. Clinical momentum included positive Phase 1 ERAS‑0015 data on April 27 and a Merck KEYTRUDA collaboration announced on May 11. Investor‑facing events have been frequent, including a Bank of America conference fireside chat on May 13. Today’s Jefferies appearance continues this pattern of active investor outreach alongside RAS/MAPK pipeline execution.
Key Terms
ras/mapk pathway medical
webcast technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, May 27, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Jefferies Global Healthcare Conference being held at the Marriott Marquis in New York, NY. Management will participate in a fireside chat on Wednesday, June 3, 2026, at 3:10 pm Eastern Time and will also participate in one-on-one investor meetings.
A live audio webcast of the event will be available online at Erasca.com/events. An archived replay of the event will be available for 30 days following the webcast at Erasca.com/events.
About Erasca
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of patients with cancer. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.
Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
